Basilea Pharmaceutica has obtained FDA orphan drug status to isavuconazole, an investigational intravenous and oral broad-spectrum antifungal, for the treatment of invasive aspergillosis. Isavuconazole is being investigated in phase 3 ...
Basilea Pharmaceutica has submitted a marketing authorization application (MAA) under the European decentralized procedure for its novel investigational antibiotic, ceftobiprole, to treat pneumonia in hospitals. The submission of the ...
Basilea Pharmaceutica has commenced next pharmacokinetic Phase 1 study with antibiotic BAL30072 in healthy volunteers. The injectable sulfactam antibiotic has the potential to target clinically relevant gram-negative bacteria resistant to ...
Basilea Pharmaceutica has selected Dotmatics' suite of solutions for pre-clinical research informatics, which allows analyzing, registering and managing scientific data. The platform provides an electronic laboratory notebook for ...
Tags: Basilea Pharmaceutica, platform, chemistry and biology experiments